

## Record of Exposure to Hazardous Drugs Group 1 and Group 2

All employees who prepare or administer hazardous drugs are required to document their daily exposure as per **Provincial Systemic Therapy Policy** <u>V-10</u>: (Hazardous Drugs Safe Handling Standards) and WorkSafe BC regulations

This Record of Exposure template contains BC Cancer approved hazardous drugs administered intravenously and by injection. **These drugs represent an occupational** hazard to healthcare workers and should always be handled with the use of recommended engineering controls (i.e. Closed System Drug Transfer Device), and personal protective equipment (PPE), regardless of dosage form. Any clinical trials drugs, oral agents or other drugs classified as hazardous and not presently on this list may be added to the blank spaces provided below.

To confirm if any drug is classified as Group 1 or Group 2 hazardous always refer to the most recent up to date BC Hazardous Drugs list and BC Cancer addendum (includes all oral agents) at: <a href="http://www.bccancer.bc.ca/drug-database-site/Documents/HD%20List.pdf">http://www.bccancer.bc.ca/drug-database-site/Documents/HD%20List.pdf</a>.

RN Name:															Ye	ar: _	 	 	Group 1		1	Group 2								
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18		20		24	25	26	27	28	29	30	31	Total
Amsacrine																														
Arsenictrioxide																														
Atezolizumab																														
Avelumab																														
Azacitidine																														
BacillusCalmette -																														
Guerin (BCG)																														
Bendamustine																														
Bleomycin																														
Blinatumomab																														
Brentuximab																														
Cabazitaxel																														
Carboplatin																														
Carfilzomib																														
Carmustine																														
*Cemiplimab																														
Cisplatin																														
Cladribine																														
Cyclo-																														
phosphamide																														
Cytarabine																														
Dacarbazine																														
Dactinomycin																														
Daunorubicin HCl																														
Dexrazoxane																														
Docetaxel																														
Doxorubicin (all																														
formulations)																														
Durvulumab																														



## Record of Exposure to Hazardous Drugs Group 1 and Group 2

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	
Epirubicin																																
Eribulin																																
Etoposide																																
Fludarabine																																
Fluorouracil																																
Gemcitabine																																
*Gemtuzumab																																
ozogamicin																																
Idarubicin																																
Ifosfamide																																
Inotuzumab																																
ozogamicin																																
Irinotecan (all																																
formulations)																																
Melphalan																																
Methotrexate																																
Mitomycin																																
Mitoxantrone																																
Oxaliplatin																																
Paclitaxel (all																																
formulations)																																
Pamidronate																																
Pemetrexed																																
Polatuzumab																																
vedotin																																
Pralatrexate																																
Raltitrexed																																
Romidepsin *Sirolimus																																
Streptozocin												-		-																		
Temsirolimus																																
Teniposide																																
Thiotepa																																
Topotecan																																
Trastuzumab																																
emtansine Vinblastine																																
Vincristine Vinorelbine																																
Zoledronic acid																																



## Record of Exposure to Hazardous Drugs Group 1 and Group 2

ALL	IN	IFC1	ΠO	NS

RN Name:														V	lonth	ո։										Yea	ar:					
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	Total
Azacitadine																																
BuserelinLA																																
(Suprefact																																
Depot)																																
Bortezomib																																
Degarelix																																
(Firmagon)																																
Fulvestrant																																
(Faslodex)																																
Goserelin																																
(Zoladex)																																
Leuprolide LA																																
(Lupron																																
depot)																																
Leuprolide (Eligard)																																
Testosterone enanthate																																

Oral agents or any additional hazardous drugs (i.e. Special Authority Program drugs) not found above may be added to the spaces below. Please confirm by checking the updated BC Provincial Hazardous Drugs list and the BC Cancer Addendum to the BC Hazardous Drug List at: <a href="http://www.bccancer.bc.ca/drug-database-site/Documents/HD%20List.pdf">http://www.bccancer.bc.ca/drug-database-site/Documents/HD%20List.pdf</a> These drugs represent an occupational hazard to healthcare workers and should always be handled with the use of recommended engineering controls and personal protective equipment (PPF), regardless of dosage form.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 3																															
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31

Updated: April 2022